{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:24Z","timestamp":1790217384292,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00417-022-05628-3","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T06:02:42Z","timestamp":1650348162000},"page":"2837-2846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis"],"prefix":"10.1007","volume":"260","author":[{"given":"Fengjie","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"5628_CR1","doi-asserted-by":"publisher","first-page":"3935945","DOI":"10.1155\/2019\/3935945","volume":"2019","author":"E Jin","year":"2019","unstructured":"Jin E, Yin H, Gui Y et al (2019) Fluorescein angiographic findings of peripheral retinal vasculature after intravitreal conbercept versus ranibizumab for retinopathy of prematurity. J Ophthalmol 2019:3935945. https:\/\/doi.org\/10.1155\/2019\/3935945","journal-title":"J Ophthalmol"},{"key":"5628_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/archdischild-2016-310532","volume":"102","author":"AL Solebo","year":"2017","unstructured":"Solebo AL, Teoh L, Rahi J (2017) Epidemiology of blindness in children. Arch Dis Child 102:853\u2013857. https:\/\/doi.org\/10.1136\/archdischild-2016-310532","journal-title":"Arch Dis Child"},{"key":"5628_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.semperi.2019.05.011","volume":"43","author":"DK VanderVeen","year":"2019","unstructured":"VanderVeen DK, Cataltepe SU (2019) Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity. Semin Perinatol 43:375\u2013380. https:\/\/doi.org\/10.1053\/j.semperi.2019.05.011","journal-title":"Semin Perinatol"},{"key":"5628_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","volume":"257","author":"EA Sukgen","year":"2019","unstructured":"Sukgen EA, Kocluk Y (2019) Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 257:49\u201355. https:\/\/doi.org\/10.1007\/s00417-018-4168-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5628_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2017","unstructured":"Zhang G, Yang M, Zeng J et al (2017) Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 37:710\u2013717. https:\/\/doi.org\/10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"5628_CR6","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","volume":"58","author":"J Lyu","year":"2017","unstructured":"Lyu J, Zhang Q, Chen CL et al (2017) Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors. Invest Ophthalmol Vis Sci 58:1719\u20131725. https:\/\/doi.org\/10.1167\/iovs.16-20680","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5628_CR7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"5628_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N et al (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 172:278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"5628_CR9","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","volume":"98","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J (2020) Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol 98:e1004\u2013e1008. https:\/\/doi.org\/10.1111\/aos.14460","journal-title":"Acta Ophthalmol"},{"key":"5628_CR10","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694. https:\/\/doi.org\/10.1001\/archopht.121.12.1684","journal-title":"Arch Ophthalmol"},{"key":"5628_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123:991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"5628_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","volume":"124","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P et al (2017) Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 124:1156\u20131164. https:\/\/doi.org\/10.1016\/j.ophtha.2017.03.018","journal-title":"Ophthalmology"},{"key":"5628_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000489023","volume":"240","author":"S Kimyon","year":"2018","unstructured":"Kimyon S, Mete A (2018) Comparison of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity affecting zone 1. Ophthalmologica 240:99\u2013105. https:\/\/doi.org\/10.1159\/000489023","journal-title":"Ophthalmologica"},{"key":"5628_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35:675\u2013680. https:\/\/doi.org\/10.1097\/IAE.0000000000000578","journal-title":"Retina"},{"key":"5628_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyama\u00e7 Sukgen","year":"2016","unstructured":"Alyama\u00e7 Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, Cevher S (2016) The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica 236:139\u2013147. https:\/\/doi.org\/10.1159\/000449530","journal-title":"Ophthalmologica"},{"key":"5628_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","volume":"16","author":"MP Blair","year":"2012","unstructured":"Blair MP, Shapiro MJ, Hartnett ME (2012) Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J AAPOS 16:234\u2013237. https:\/\/doi.org\/10.1016\/j.jaapos.2011.12.157","journal-title":"J AAPOS"},{"key":"5628_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","volume":"198","author":"TA Chen","year":"2019","unstructured":"Chen TA, Shields RA, Bodnar ZH, Callaway NF, Schachar IH, Moshfeghi DM (2019) A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am J Ophthalmol 198:63\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039","journal-title":"Am J Ophthalmol"},{"key":"5628_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical Management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"key":"5628_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122:1008\u20131015. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology"},{"key":"5628_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Darida M (2017) Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97\u2013111. https:\/\/doi.org\/10.1097\/IAE.0000000000001126","journal-title":"Retina"},{"key":"5628_CR21","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","volume":"39","author":"A Vural","year":"2019","unstructured":"Vural A, Ekinci DY, Onur IU, Hergunsel GO, Yigit FU (2019) Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Int Ophthalmol 39:2267\u20132274. https:\/\/doi.org\/10.1007\/s10792-018-01064-7","journal-title":"Int Ophthalmol"},{"key":"5628_CR22","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252\u20137259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713","journal-title":"Clin Cancer Res"},{"key":"5628_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12032-012-0390-x","volume":"30","author":"JX Zhang","year":"2013","unstructured":"Zhang JX, Cai MB, Wang XP et al (2013) Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol 30:390. https:\/\/doi.org\/10.1007\/s12032-012-0390-x","journal-title":"Med Oncol"},{"key":"5628_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/jovr.jovr_198_16","volume":"13","author":"R Karkhaneh","year":"2018","unstructured":"Karkhaneh R, Torabi H, Khodabande A, Roohipoor R, Riazi-Esfahani M (2018) Efficacy of intravitreal bevacizumab for the treatment of zone I type 1 retinopathy of prematurity. J Ophthalmic Vis Res 13:29\u201333. https:\/\/doi.org\/10.4103\/jovr.jovr_198_16","journal-title":"J Ophthalmic Vis Res"},{"key":"5628_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","volume":"124","author":"J Feng","year":"2017","unstructured":"Feng J, Qian J, Jiang Y et al (2017) Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China. Ophthalmology 124:408\u2013409. https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.032","journal-title":"Ophthalmology"},{"key":"5628_CR26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK et al (2020) Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina 40:1793\u20131803. https:\/\/doi.org\/10.1097\/IAE.0000000000002663","journal-title":"Retina"},{"key":"5628_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","volume":"18","author":"Q Tong","year":"2018","unstructured":"Tong Q, Yin H, Zhao M, Li X, Yu W (2018) Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol 18:150. https:\/\/doi.org\/10.1186\/s12886-018-0815-1","journal-title":"BMC Ophthalmol"},{"key":"5628_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ophtha.2010.04.021","volume":"118","author":"D Lepore","year":"2011","unstructured":"Lepore D, Molle F, Pagliara MM et al (2011) Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity. Ophthalmology 118:168\u2013175. https:\/\/doi.org\/10.1016\/j.ophtha.2010.04.021","journal-title":"Ophthalmology"},{"key":"5628_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","volume":"4","author":"AE Hamad","year":"2020","unstructured":"Hamad AE, Moinuddin O, Blair MP et al (2020) Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol Retina 4:602\u2013612. https:\/\/doi.org\/10.1016\/j.oret.2019.12.015","journal-title":"Ophthalmol Retina"},{"key":"5628_CR30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38:764\u2013772. https:\/\/doi.org\/10.1097\/IAE.0000000000001581","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05628-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T10:06:46Z","timestamp":1661508406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5628"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05628-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"19 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the tenets of the Declaration of Helsinki and approved by the Ethics Committee of Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China (Approval No. XHEC-D-2018\u2013020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the parents for all examinations, treatments, and data analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All study subjects gave informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}